trava semaglutide – Trying Trava for my GLP1

PCCA members with clinical services access may contact our Clinical Services team for help with sublingual semaglutide and other compounding concerns.

Thyroid function should be monitored at baseline, 812 weeks after starting treatment, and during significant weight changes to ensure optimal dosing

Gastrointestinal adverse effects (nausea, vomiting, diarrhoea) occur at similar frequencies to other GLP-1 receptor agonists, affecting approximately 12% to 24% of patients (nausea being most common), and are typically more frequent during dose escalation

In Phase 2 trials, Retatrutide produced weight loss of up to 24.2% of body weight over 48 weeks

Studies have also explored improvements in cardiometabolic markers including HbA1c, fasting glucose, cholesterol, triglycerides, and non-alcoholic fatty liver disease